Suprax contains cefixime, a broad-spectrum bactericidal antibacterial agent, and is registered in 17 countries across Europe, the Middle East, North Africa, the Caucasus, and East Asia. The brand is used in the management of a range of bacterial infections rather than confined to a single therapy area.
The indications registered for Suprax include respiratory infections such as bronchitis and pneumonia, urinary tract infections, middle ear infections including chronic forms, and gonorrhoea. As a broad-spectrum antibacterial, cefixime is used where the suspected or confirmed pathogen is sensitive to its mechanism — the structured indication block further down this page lists each registered use in detail for the markets where Suprax is sold.
The country list points to a footprint shaped more by regional regulatory history than by any single market. Suprax is encountered by travellers and expatriates in places as varied as Canada, Egypt, Russia, Italy, China, Turkey, and Lebanon, with packaging, prescription pathways, and pack sizes varying considerably from one jurisdiction to another. A patient who has been prescribed Suprax in one country and is travelling or relocating to another may find the same brand on the shelf, a different cefixime-containing brand, or a locally produced generic.
Other antibacterial agents in the broader bactericidal category exist worldwide under different molecules and brand names, and they are not freely interchangeable — antibiotic selection depends on the specific infection, local resistance patterns, and individual clinical context. A local pharmacist can confirm regional brand names for cefixime, but the decision to start, continue, or substitute any antibacterial therapy belongs with a prescribing healthcare provider.
Suprax is prescribed for a range of bacterial infections, including respiratory conditions such as bronchitis and pneumonia, urinary tract infections, middle ear infections including chronic forms, and gonorrhoea. As a broad-spectrum antibacterial, it is used where the suspected or confirmed pathogen is sensitive to its mechanism. The structured indication block further down this page details each registered use across the markets where Suprax is sold.
Suprax contains cefixime, classified as a broad-spectrum bactericidal antibacterial agent. Cefixime is the same molecule wherever it appears, whether labelled as Suprax or sold as a generic — internationally, the active ingredient circulates under several commercial names, particularly in markets where multiple manufacturers produce cefixime-containing products in parallel.
Suprax is registered in 17 countries, spanning parts of Europe, the Middle East, North Africa, the Caucasus, and East Asia. Examples include Canada, Egypt, Russia, Italy, China, Lebanon, and Turkey. If your country is not represented in this list, a local pharmacist can usually confirm whether cefixime is available in that market under a different brand name or as a generic preparation.
Cefixime is marketed under several brand names worldwide, particularly in regions where multiple manufacturers produce the molecule. Other antibacterial agents in the broader bactericidal category also exist, although they are not interchangeable without medical guidance — antibiotics differ in spectrum, route, and clinical positioning. To identify a local cefixime-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Antibacterial therapy is calibrated to the specific infection, the suspected pathogen, and the patient's individual circumstances, and inappropriate antibiotic use carries both individual and public-health consequences. Prescription rules, pack sizes, and available formulations of cefixime vary between countries, which is particularly relevant for travellers and people relocating. Any decision to start, continue, or substitute Suprax should be made in consultation with a healthcare provider.
